X Y Jian

ORCID: 0000-0001-8228-0509
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastrointestinal Tumor Research and Treatment
  • Lymphoma Diagnosis and Treatment
  • Systemic Lupus Erythematosus Research
  • Lung Cancer Treatments and Mutations
  • Gastric Cancer Management and Outcomes
  • Renal Diseases and Glomerulopathies
  • Metastasis and carcinoma case studies
  • Cancer Immunotherapy and Biomarkers
  • Liver Disease Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Immune Cell Function and Interaction
  • Vascular Tumors and Angiosarcomas
  • Meta-analysis and systematic reviews

Guangzhou Medical University
2024

First Affiliated Hospital of Zhengzhou University
2021-2024

Southern University of Science and Technology
2024

Background. In this research, programmed cell death protein 1 (PD-1) inhibitors, including toripalimab, sintilimab, and camrelizumab, were evaluated for the treatment of non-small-cell lung cancer (NSCLC). Methods. This retrospective research was conducted on patients with locally advanced NSCLC receiving various PD-1 inhibitors between April 2019 March 2023. Results. total, ORR DCR 167 included in 40.72% (68/167) 92.81% (155/167), respectively, while statistical median PFS 13.90 months (95%...

10.1155/2024/6004679 article EN European Journal of Cancer Care 2024-03-19

To investigate the clinicopathological, immunophenotypic and molecular genetic characteristics, differential diagnosis of NTRK-rearranged spindle cell neoplasms (NTRK-RSCNs) in gastrointestinal tract.

10.3760/cma.j.cn112151-20231020-00280 article EN PubMed 2024-06-08

Objective: To investigate the clinicopathological features, molecular genetics, treatment and prognosis of Burkitt-like lymphoma with 11q aberration (BLL-11q). Methods: Six cases BLL-11q diagnosed at First Affiliated Hospital Zhengzhou University, from January 2016 to 2020 were reviewed analyzed using hematoxylin-eosin staining, immunohistochemistry, EBER in situ hybridization fluorescence hybridization. Clinical information including follow-up data was collected analyzed. Results: The...

10.3760/cma.j.cn112151-20210204-00127 article EN PubMed 2021-06-08

目的: 探讨血管免疫母细胞性T细胞淋巴瘤(AITL)累及胃肠道的临床病理学特点、诊断及预后。 方法: 收集郑州大学第一附属医院2021年9月诊断的1例肠道活检的AITL,复习临床特点,行HE染色、免疫组织化学、EB病毒编码的RNA(EBER)原位杂交、T细胞受体(TCR)基因重排(BIOMED2法)及二代测序检测1 166个基因,并复习总结文献中报道的AITL累及胃肠道的特征。 结果: 患者女,53岁,肠镜示回盲部至直肠多发结节状、息肉样隆起;HE示典型AITL的形态,肿瘤主要浸润黏膜固有层,局部侵及黏膜下层,未见固有腺体侵犯及黏膜表面溃疡;免疫组织化学:肿瘤细胞表达T系标志物(CD3、CD4、CD5)及滤泡辅助T细胞标志物(PD-1及CXCL13),CD21示滤泡树突状细胞网增生紊乱,Ki-67阳性指数约40%;EBER原位杂交见散在细胞阳性;二代测序检测发现3组融合基因:EIF4E3-FOXP1、RP11-434C1.1-ETV6、RP11-380O24.1-SRGAP3。随访2个月,患者化疗1个疗程后因肠出血死亡。 结论:...

10.3760/cma.j.cn112151-20220105-00006 article ZH-CN PubMed 2022-08-08
Coming Soon ...